This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Pancreatic cancer	HER2 (EGFR2; ErbB2; neu); CD3; T cell receptor (TCR)	<p>Mouse and <i>in vitro</i> studies suggest bispecific antibodies targeting HER2 and either CD3 or the Vγ9 TCR could help eliminate pancreatic cancer cells. In cocultures of human pancreatic cancer cell lines with human γδ T cells activated by synthetic phosphoantigen, addition of bispecific antibodies targeting HER2 and either CD3 or Vγ9 TCR increased the cytotoxic effect of γδT cells on cancer cells compared with no treatment. In a mouse xenograft model of pancreatic cancer, the antibody targeting HER2 and Vγ9 TCR enhanced the antitumor cytotoxicity of adoptively transferred γδ T cells. Next steps could include testing the bispecific antibody in additional mouse models of pancreatic cancer in comparison with individual HER2- and CD3- or Vγ9 TCR-specific antibodies.</p> <p>SciBX 7(9); doi:10.1038/scibx.2014.254 Published online March 6, 2014</p>	Patent and licensing status unavailable	<p>Oberg, H.-H. <i>et al. Cancer Res.</i>; published online Jan. 21, 2014; doi:10.1158/0008-5472.CAN-13-0675 Contact: Daniela Wesch, Kiel University, Kiel, Germany e-mail: wesch@immunologie.uni-kiel.de</p>